Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.

In the non‐intensive pathway there was a small but highly significant difference in favour of CTDa for Pain at 3 months with a persistent trend for benefit at 6 and 12 months (Pain lower for CTDa, 3 months: −8·88 [95% CI −13·58, −4·18], P = 0·0002; 6 months: −4·82 [95% CI −9·91, 0·26], P = 0·06; 12 months: −4·57 [95% CI −11·96, 2·81], P = 0·22, Fig 2 B).

also in 132,142 other papers